FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of BPC 157 Banned: Key Facts on the Latest FDA Decision FDA Peptide Reclassification 2026: What Researchers Want